Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS

BACKGROUND: We explored the effect of teriflunomide on cortical gray matter (CGM) and whole brain (WB) atrophy in patients with clinically isolated syndrome (CIS) from the phase III TOPIC study and assessed the relationship between atrophy and risk of conversion to clinically definite MS (CDMS). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Zivadinov, Robert, Dwyer, Michael G., Carl, Ellen, Poole, Elizabeth M., Cavalier, Steve, Briassouli, Paraskevi, Bergsland, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672760/
https://www.ncbi.nlm.nih.gov/pubmed/33240397
http://dx.doi.org/10.1177/1756286420970754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672760/
https://www.ncbi.nlm.nih.gov/pubmed/33240397
http://dx.doi.org/10.1177/1756286420970754

Ejemplares similares